Molecular Biology Reports

, Volume 39, Issue 12, pp 10089–10096 | Cite as

Overexpression of tissue factor pathway inhibitor in CHO-K1 cells results in increased activation of NF-κB and apoptosis mediated by a caspase-3 independent pathway

  • Grethe SkrettingEmail author
  • Nina Iversen
  • Christiane F. Myklebust
  • Anders E. Dahm
  • Per Morten Sandset


There is now circumstantial evidence that tissue factor pathway inhibitor (TFPI) is not only a major anticoagulant, but also has proapoptotic properties. The current study was designed to address the role of TFPI on signalling pathways and apoptosis. The non-TFPI expressing cell line CHO-K1 was stably transfected with pcDNA3.1/V5-His-TOPO-TFPI and control cells were established by transfecting the CHO-K1 cells with pcDNA3.1/V5-His-TOPO. Sodium butyrate (NaBut) has been shown to induce the expression of recombinant proteins. Here we have used NaBut to increase the expression of TFPI as assessed by qRT-PCR and ELISA. Compared to the control cells, TFPI induced apoptosis in a concentration dependent manner as measured by a cell death detection assay. Independent of caspase-3 activation an increased cleavage of PARP was detected in the TFPI expressing cells. This was accompanied by downregulation of Bcl-XL, elevated levels of Bax, and increased translocation of the apoptosis initiating factor. Increased DNA binding activity of NF-κB was revealed by electrophoretic mobility shift assay when the TFPI level was elevated by NaBut together with an increased translocation of the NF-κB subunit p65. The results indicate that TFPI affected the apoptotic activity through a process independent of caspase-3, and was also able to increase the activation of the NF- κB pathway.


Tissue factor pathway inhibitor CHO-K1 cells Apoptosis NF-κB Anti-cancer Na-butyrate 



The authors are grateful for the technical assistance of Erle Solheim. The study was financially supported by Grants from the Norwegian South-Eastern Health Authority.


  1. 1.
    Sandset PM, Warn-Cramer BJ, Rao LV, Maki SL, Rapaport SI (1991) Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 88:708–712PubMedCrossRefGoogle Scholar
  2. 2.
    Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ Jr (1989) Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 338:518–520PubMedCrossRefGoogle Scholar
  3. 3.
    Kurer MA (2007) Protein and mRNA expression of tissue factor pathway inhibitor-1 (TFPI-1) in breast, pancreatic and colorectal cancer cells. Mol Biol Rep 34:221–224PubMedCrossRefGoogle Scholar
  4. 4.
    Lindahl AK, Sandset PM, Abildgaard U, Andersson TR, Harbitz TB (1989) High plasma levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced cancer. Acta Chir Scand 155:389–393PubMedGoogle Scholar
  5. 5.
    Iversen N, Lindahl AK, Abildgaard U (1998) Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br J Haematol 102:889–895PubMedCrossRefGoogle Scholar
  6. 6.
    Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SJ, Pribluda VS (2003) Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 63:2997–3000PubMedGoogle Scholar
  7. 7.
    Dong X, Song L, Zhu D, Zhang H, Liu L, Leng X (2011) Tissue factor pathway inhibitor suppresses the growth of human vascular smooth muscle cells through regulating cell cycle. Mol Biol Rep 38:4771–4776PubMedCrossRefGoogle Scholar
  8. 8.
    Fu Y, Zhang Z, Zhang G, Liu Y, Cao Y, Yu J, Hu J, Yin X (2008) Adenovirus-mediated gene transfer of tissue factor pathway inhibitor induces apoptosis in vascular smooth muscle cells. Apoptosis 13:634–640PubMedCrossRefGoogle Scholar
  9. 9.
    Dong X, Song LP, Zhu DW, Zhang HL, Liu LX, Leng XG (2011) Impact of the tissue factor pathway inhibitor gene on apoptosis in human vascular smooth muscle cells. Genet Mol Biol 34:25–30PubMedCrossRefGoogle Scholar
  10. 10.
    Stavik B, Skretting G, Sletten M, Sandset PM, Iversen N (2010) Overexpression of both TFPIalpha and TFPIbeta induces apoptosis and expression of genes involved in the death receptor pathway in breast cancer cells. Mol Carcinog 49:951–963PubMedCrossRefGoogle Scholar
  11. 11.
    Stavik B, Skretting G, Aasheim HC, Tinholt M, Zernichow L, Sletten M, Sandset PM, Iversen N (2011) Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility. BMC Cancer 11:357PubMedCrossRefGoogle Scholar
  12. 12.
    Karin M, Lin A (2002) NF-kappaB at the crossroads of life and death. Nat Immunol 3:221–227PubMedCrossRefGoogle Scholar
  13. 13.
    Graham B, Gibson SB (2005) The two faces of NFkappaB in cell survival responses. Cell Cycle 4:1342–1345PubMedCrossRefGoogle Scholar
  14. 14.
    Chen Y, Wang J, Yao Y, Yuan W, Kong M, Lin Y, Geng D, Nie R (2009) CRP regulates the expression and activity of tissue factor as well as tissue factor pathway inhibitor via NF-kappaB and ERK 1/2 MAPK pathway. FEBS Lett 583:2811–2818PubMedCrossRefGoogle Scholar
  15. 15.
    Jin H, Qiu WB, Mei YF, Wang DM, Li YG, Tan XR (2009) Testosterone alleviates tumor necrosis factor-alpha-mediated tissue factor pathway inhibitor downregulation via suppression of nuclear factor-kappa B in endothelial cells. Asian J Androl 11:266–271PubMedCrossRefGoogle Scholar
  16. 16.
    Pajak B, Gajkowska B, Orzechowski A (2009) Sodium butyrate sensitizes human colon adenocarcinoma COLO 205 cells to both intrinsic and TNF-alpha-dependent extrinsic apoptosis. Apoptosis 14:203–217PubMedCrossRefGoogle Scholar
  17. 17.
    Reuter S, Eifes S, Dicato M, Aggarwal BB, Diederich M (2008) Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol 76:1340–1351PubMedCrossRefGoogle Scholar
  18. 18.
    Barkett M, Gilmore TD (1999) Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 18:6910–6924PubMedCrossRefGoogle Scholar
  19. 19.
    Lauder A, Castellanos A, Weston K (2001) c-Myb transcription is activated by protein kinase B (PKB) following interleukin 2 stimulation of Tcells and is required for PKB-mediated protection from apoptosis. Mol Cell Biol 21:5797–5805PubMedCrossRefGoogle Scholar
  20. 20.
    Cummings JH (1981) Short chain fatty acids in the human colon. Gut 22:763–779PubMedCrossRefGoogle Scholar
  21. 21.
    Heerdt BG, Houston MA, Augenlicht LH (1994) Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Res 54:3288–3293PubMedGoogle Scholar
  22. 22.
    Singh B, Halestrap AP, Paraskeva C (1997) Butyrate can act as a stimulator of growth or inducer of apoptosis in human colonic epithelial cell lines depending on the presence of alternative energy sources. Carcinogenesis 18:1265–1270PubMedCrossRefGoogle Scholar
  23. 23.
    Barnard JA, Warwick G (1993) Butyrate rapidly induces growth inhibition and differentiation in HT-29 cells. Cell Growth Differ 4:495–501PubMedGoogle Scholar
  24. 24.
    Jiang Z, Sharfstein ST (2008) Sodium butyrate stimulates monoclonal antibody over-expression in CHO cells by improving gene accessibility. Biotechnol Bioeng 100:189–194PubMedCrossRefGoogle Scholar
  25. 25.
    Place RF, Noonan EJ, Giardina C (2005) HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. Biochem Pharmacol 70:394–406PubMedCrossRefGoogle Scholar
  26. 26.
    Rodrigues GH, Arthuso FS, Capone MV, de Oliveira TL, Bartolini P, Soares CR (2010) Enhancement of human prolactin synthesis by sodium butyrate addition to serum-free CHO cell culture. J Biomed Biotechnol 2010:405872Google Scholar
  27. 27.
    Skretting G, Lien T, Sandset PM, Iversen N (2009) Expression of the V264M TFPI mutant in endothelial cell cultures may involve mRNA stability. Thromb Res 123:851–855PubMedCrossRefGoogle Scholar
  28. 28.
    Dahm A, Van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina RM, Sandset PM (2003) Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 101:4387–4392PubMedCrossRefGoogle Scholar
  29. 29.
    Yu SW, Andrabi SA, Wang H, Kim NS, Poirier GG, Dawson TM, Dawson VL (2006) Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci USA 103:18314–18319PubMedCrossRefGoogle Scholar
  30. 30.
    Pastorino JG, Chen ST, Tafani M, Snyder JW, Farber JL (1998) The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition. J Biol Chem 273(13):7770–7775PubMedCrossRefGoogle Scholar
  31. 31.
    Lin YF, Zhang N, Guo HS, Kong DS, Jiang T, Liang W, Zhao ZH, Tang QQ, Ma D (2007) Recombinant tissue factor pathway inhibitor induces apoptosis in cultured rat mesangial cells via its Kunitz-3 domain and C-terminal through inhibiting PI3-kinase/Akt pathway. Apoptosis 12:2163–2173PubMedCrossRefGoogle Scholar
  32. 32.
    Inan MS, Rasoulpour RJ, Yin L, Hubbard AK, Rosenberg DW, Giardina C (2000) The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line. Gastroenterology 118:724–734PubMedCrossRefGoogle Scholar
  33. 33.
    Vlahos CJ, Matter WF, Hui KY, Brown RF (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269:5241–5248PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Grethe Skretting
    • 1
    • 2
    Email author
  • Nina Iversen
    • 3
    • 4
  • Christiane F. Myklebust
    • 1
    • 2
  • Anders E. Dahm
    • 1
    • 2
  • Per Morten Sandset
    • 1
    • 2
    • 5
  1. 1.Department of HaematologyOslo University HospitalOsloNorway
  2. 2.Research Institute of Internal MedicineOslo University HospitalOsloNorway
  3. 3.Department of Medical GeneticsOslo University HospitalOsloNorway
  4. 4.University of OsloOsloNorway
  5. 5.Institute of Clinical MedicineUniversity of OsloOsloNorway

Personalised recommendations